PMID- 35048998
OWN - NLM
STAT- MEDLINE
DCOM- 20220407
LR  - 20220407
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 26
IP  - 1
DP  - 2022 Jan
TI  - Effects of edaravone combined with Oxiracetam on neuronal apoptosis in rats with 
      cerebral infarction through targeting SIRT1/NF-kappaB inflammatory pathway.
PG  - 218-224
LID - 27771 [pii]
LID - 10.26355/eurrev_202201_27771 [doi]
AB  - OBJECTIVE: The objective of this study was to investigate the effects of 
      edaravone combined with oxiracetam on neuronal apoptosis in rats with cerebral 
      infarction (CI) and to explore the potential molecular mechanism. MATERIALS AND 
      METHODS: A total of 36 Sprague-Dawley rats were randomly divided into 
      sham-operation group (n=12), model group (n=12) and treatment group (n=12). Only 
      the external carotid artery was exposed in sham-operation group, while the models 
      of CI were established using suture method in the other two groups. After 
      modeling, the rats in sham-operation group and model group were intraperitoneally 
      injected with normal saline, and those in treatment group were administered with 
      edaravone and oxiracetam solutions via intraperitoneal injection. Then, the 
      specimens were obtained at 2 weeks after intervention. The cognitive function of 
      the rats was evaluated using a water maze, Nissl staining was applied to observe 
      the neuronal morphology, and the relative protein expressions of silent 
      information regulator 1 (SIRT1) and NF-kappaB were measured by means of Western 
      blotting. Furthermore, quantitative polymerase chain reaction (qPCR) was 
      performed to determine the messenger ribonucleic acid (mRNA) expressions of 
      interleukin-1 beta (IL-1beta) and IL-6, the content of IL-1beta and IL-6 was detected 
      by enzyme-linked immunosorbent assay (ELISA), and terminal deoxynucleotidyl 
      transferase-mediated dUTP nick end labeling (TUNEL) assay was conducted to 
      examine the cell apoptosis. RESULTS: Model group displayed a significantly longer 
      escape latency and significantly fewer times of crossing the original platform 
      than sham-operation group (p<0.05), whereas treatment group had a significantly 
      shorter escape latency but significantly more times of crossing the original 
      platform than model group (p<0.05). The relative protein expression level of 
      SIRT1 was lowered significantly, while that of NF-kappaB was elevated significantly 
      in model group in comparison with those in sham-operation group (p<0.05), and the 
      opposite results were observed between model group and treatment group (p<0.05). 
      Besides, the content of IL-1beta and IL-6 in brain tissues was increased 
      significantly in model group compared with that in sham-operation group (p<0.05), 
      but it was decreased significantly in treatment group in comparison with that in 
      model group (p<0.05). The relative mRNA expression levels of IL-1beta and IL-6 were 
      significantly higher in model group than those in sham-operation group (p<0.05). 
      Moreover, model group exhibited more positive apoptotic cells and a significantly 
      higher apoptosis rate than sham-operation group (p<0.05) and treatment group 
      (p<0.05). No apparent abnormalities of neuronal morphology and structure were 
      detected in sham-operation group, with many Nissl bodies. The neurons were 
      damaged, with abnormal morphology and structure, and there were a small number of 
      Nissl bodies in model group. The neurons were damaged in treatment group, but 
      their morphology and structure were improved evidently compared with those in 
      model group. CONCLUSIONS: Edaravone combined with oxiracetam can inhibit the 
      neuronal apoptosis in CI rats by regulating the SIRT1/NF-kappaB signaling pathway, 
      thereby exerting a neuroprotective effect.
FAU - Cui, X-P
AU  - Cui XP
AD  - Department of Neurology, 900th Hospital of Joint Logistics Support Force and 
      Fuzong Clinical Medical College of Fujian Medical University, Fuzhou, Fujian, 
      China. mujs@163.com.
FAU - Ye, J-X
AU  - Ye JX
FAU - Lin, H
AU  - Lin H
FAU - Zhou, H
AU  - Zhou H
FAU - Ye, S
AU  - Ye S
FAU - Mu, J-S
AU  - Mu JS
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (NF-kappa B)
RN  - 0 (Pyrrolidines)
RN  - EC 3.5.1.- (Sirt1 protein, rat)
RN  - EC 3.5.1.- (Sirtuin 1)
RN  - P7U817352G (oxiracetam)
RN  - S798V6YJRP (Edaravone)
SB  - IM
MH  - Animals
MH  - Apoptosis
MH  - Cerebral Infarction/metabolism
MH  - Edaravone/pharmacology
MH  - *NF-kappa B/metabolism
MH  - Pyrrolidines
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - *Sirtuin 1
EDAT- 2022/01/21 06:00
MHDA- 2022/04/08 06:00
CRDT- 2022/01/20 09:07
PHST- 2022/01/20 09:07 [entrez]
PHST- 2022/01/21 06:00 [pubmed]
PHST- 2022/04/08 06:00 [medline]
AID - 27771 [pii]
AID - 10.26355/eurrev_202201_27771 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2022 Jan;26(1):218-224. doi: 
      10.26355/eurrev_202201_27771.